Close Menu

NEW YORK – DiaSorin Molecular has received US Food and Drug Administration clearance for its Simplexa VZV Swab Direct assay to detect varicella-zoster virus (VZV) DNA from cutaneous and mucocutaneous swab specimens, the firm announced on Tuesday.

The CLIA moderate complexity assay is designed for use on Diasorin's Liaison MDX instrument, which leverages real-time PCR technology. The firm said the test complements its Simplexa VZV Direct kit, which uses cerebrospinal fluid samples.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.